EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

New-Onset Complement-Mediated Thrombotic Microangiopathy during the COVID-19 Pandemic

Christof Aigner, Martina Gaggl, Sophie Schmidt, Renate Kain, Nicolas Kozakowski, André Oszwald, Zoltán Prohászka, Raute Sunder-Plassmann, Alice Schmidt, Gere Sunder-Plassmann

Kidney and Blood Pressure Research · 2024

DOI: 10.1159/000541938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, 2024. Verfasst von Christof Aigner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Thrombotic Microangiopathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus is alleged to enable a proinflammatory state that leads to the activation of the coagulation and the complement cascade. In this study, we aimed to establish the impact of the COVID-19 pandemic on patients with new onset of cTMA/aHUS in the Vienna TMA cohort and whether COVID-19 or SARS-CoV-2 vaccinations would pose a greater risk of initial manifestation of cTMA/aHUS.

Methods

We used the Vienna TMA cohort database to examine the prevalence of COVID-19-related and of SARS-CoV-2 vaccination-related aHUS/cTMA during the first 3 years of the COVID-19 pandemic in a large single-centre cohort.

Results

Between March 2020 and May 2023, a total of 7 patients experienced their first aHUS/cTMA episode. No patient experienced a TMA relapse or more than one episode during the follow-up period. Three TMA episodes were attributable to either COVID-19 (n = 1; 33%) or SARS-CoV-2 vaccination (n = 2; 66%), respectively. All 3 patients had systemic signs of TMA, and TMA was confirmed by kidney biopsy in all cases. Among the 7 patients, we recorded five infections that triggered one TMA episode (20%) and 19 vaccinations triggered two TMA episodes (10%; p = 0.52, odds ratio 0.47; 95% CI: 0.04–8.39).

Conclusion

We speculate that both SARS-CoV-2 vaccinations and COVID-19 episodes can represent a triggering factor for aHUS/cTMA episodes in (genetically) vulnerable individuals. However, COVID-19 might have a stronger association and might be a stronger trigger than the SARS-CoV-2 vaccines. The incidence of new aHUS cases did not differ from the pre-pandemic era in a large tertiary care centre cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesThrombotic MicroangiopathiesAdultAgedFemaleHumansMaleMiddle AgedCohort StudiesComplement System Proteins

Stichwörter der Autor:innen

COVID-19Genetic renal diseaseHaemolytic uremic syndromeSARS-CoV-2Thrombotic microangiopathyVaccination

Substanzen

Complement System ProteinsCOVID-19 Vaccines

Autor:innen und Institutionen

  • Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Department of Pathology, Medical University of Vienna, Vienna, Austria.
  • Research Laboratory, Department of Internal Medicine and Haematology, and Research Group for Immunology and Haematology, Semmelweis University - Eötvös Loránd Research Network (Office for Supported Research Groups), Bud…
  • Genetics Laboratory, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Zitieren

APA

Aigner, C., Gaggl, M., Schmidt, S., Kain, R., Kozakowski, N., Oszwald, A., Prohászka, Z., Sunder-Plassmann, R., Schmidt, A., & Sunder-Plassmann, G. (2024). New-Onset Complement-Mediated Thrombotic Microangiopathy during the COVID-19 Pandemic. Kidney and Blood Pressure Research. https://doi.org/10.1159/000541938

Vancouver

Aigner C, Gaggl M, Schmidt S, Kain R, Kozakowski N, Oszwald A, et al. New-Onset Complement-Mediated Thrombotic Microangiopathy during the COVID-19 Pandemic. Kidney and Blood Pressure Research. 2024. doi:10.1159/000541938

BibTeX
@article{Aigner2024,
  author = {Aigner, Christof and Gaggl, Martina and Schmidt, Sophie and Kain, Renate and Kozakowski, Nicolas and Oszwald, André and Prohászka, Zoltán and Sunder-Plassmann, Raute and Schmidt, Alice and Sunder-Plassmann, Gere},
  title = {New-Onset Complement-Mediated Thrombotic Microangiopathy during the COVID-19 Pandemic},
  journal = {Kidney and Blood Pressure Research},
  year = {2024},
  doi = {10.1159/000541938}
}
Kostenlos starten →